성장을 멈추지 마세요

체험은 만족하셨나요?

현재 45,766명이 마이메르시로 공부 중이에요

지식 자료를 소장하고 멋진 의료인으로 성장하세요

학습 자료 둘러보기 →
Antiparkinsonian Medications | 마이메르시 MyMerci
제안하기

뭔가 하고 싶은 말이 있는거야?

0 / 2000
컨텐츠 수정하기

컨텐츠 내용을 수정할 수 있습니다

수정하기
닫기

Antiparkinsonian Medications

NCLEX Review Guide: Parkinson's Disease Medications

Pathophysiology Review

Understanding Parkinson's Disease

  • Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by the destruction of dopaminergic neurons in the substantia nigra of the basal ganglia, resulting in dopamine deficiency and an imbalance between dopamine and acetylcholine.
  • The four cardinal symptoms include bradykinesia (slowness of movement), resting tremor, rigidity, and postural instability, which typically begin unilaterally before progressing bilaterally.

Key Points

  • PD results from dopamine deficiency in the nigrostriatal pathway
  • The dopamine-acetylcholine balance is disrupted, leading to motor symptoms
  • Non-motor symptoms include cognitive impairment, depression, and autonomic dysfunction

Dopaminergic Medications

Levodopa/Carbidopa (Sinemet)

  • Levodopa is the precursor to dopamine that crosses the blood-brain barrier and converts to dopamine in the brain, while carbidopa prevents peripheral conversion of levodopa to dopamine, reducing systemic side effects.
  • Considered the gold standard and most effective treatment for managing motor symptoms of Parkinson's disease, especially for bradykinesia and rigidity.

Key Points

  • Administer with meals if GI upset occurs, but protein may interfere with absorption
  • Effectiveness diminishes over time ("wearing-off phenomenon")
  • Long-term use associated with motor fluctuations and dyskinesias

Important Alert: Monitor for orthostatic hypotension, especially when initiating therapy. Instruct patients to change positions slowly and monitor blood pressure regularly.

Memory Aid: "LOCO for Levodopa"

L - Levodopa crosses the BBB
O - Only works when converted to dopamine
C - Carbidopa prevents peripheral conversion
O - Orthostatic hypotension is a common side effect

Dopamine Agonists

  • Dopamine agonists directly stimulate dopamine receptors in the brain, bypassing the degenerating dopaminergic neurons, and include non-ergot derivatives like pramipexole (Mirapex) and ropinirole (Requip).
  • Often used as initial therapy in younger patients or as adjunctive therapy with levodopa to reduce motor fluctuations and allow for lower levodopa doses.

Key Points

  • Less effective than levodopa but associated with fewer motor fluctuations
  • Require slow titration to minimize side effects
  • Associated with impulse control disorders (gambling, hypersexuality, shopping)

Clinical Scenario

A 62-year-old male patient with Parkinson's disease on pramipexole reports increased urges to gamble and engage in excessive online shopping. These behaviors began after his medication dose was increased. This represents a common side effect of dopamine agonists known as impulse control disorders, requiring dose adjustment or medication change.

COMT Inhibitors

  • Catechol-O-methyltransferase (COMT) inhibitors such as entacapone (Comtan) and tolcapone (Tasmar) block the peripheral metabolism of levodopa, extending its half-life and availability to the brain.
  • Always administered with levodopa/carbidopa to prolong dopaminergic stimulation and manage "wearing-off" fluctuations in patients with advanced disease.

Key Points

  • Entacapone is more commonly used due to better safety profile
  • Tolcapone requires liver function monitoring due to risk of hepatotoxicity
  • May cause orange discoloration of urine (harmless but important to warn patients)

MAO-B Inhibitors

  • Monoamine oxidase type B (MAO-B) inhibitors including selegiline (Eldepryl) and rasagiline (Azilect) prevent the breakdown of dopamine in the brain, increasing its availability at synapses.
  • Can be used as monotherapy in early disease or as adjunct to levodopa in advanced disease to extend "on" time and reduce motor fluctuations.

Key Points

  • Selective for MAO-B at recommended doses, reducing risk of tyramine interactions
  • Selegiline metabolizes to amphetamine derivatives (may cause insomnia)
  • Rasagiline has no amphetamine metabolites and once-daily dosing

Important Alert: Avoid concomitant use with meperidine, tramadol, SSRIs, and SNRIs due to risk of serotonin syndrome. Patients should be educated about potential drug interactions.

Anticholinergic Medications

Anticholinergics

  • Anticholinergic agents such as trihexyphenidyl (Artane) and benztropine (Cogentin) block cholinergic receptors to restore the balance between dopamine and acetylcholine in the basal ganglia.
  • Primarily effective for tremor and less effective for bradykinesia or rigidity; use is limited by significant side effects, especially in elderly patients.

Key Points

  • Most effective for tremor-predominant PD
  • Contraindicated in patients with glaucoma, prostatic hypertrophy, or cognitive impairment
  • Side effects include dry mouth, blurred vision, urinary retention, constipation, and confusion

Memory Aid: "Anticholinergic Side Effects: DUMB"

D - Dry mouth
U - Urinary retention
M - Mental changes (confusion)
B - Blurred vision

Amantadine

Amantadine (Symmetrel)

  • Originally developed as an antiviral agent, amantadine enhances dopamine release, blocks dopamine reuptake, and has mild anticholinergic properties, providing modest symptomatic benefit in early PD.
  • Uniquely effective for managing levodopa-induced dyskinesias in advanced disease while maintaining antiparkinsonian effects.

Key Points

  • Modest efficacy as monotherapy; benefits may diminish over 6-12 months
  • Requires dose adjustment in renal impairment
  • Side effects include livedo reticularis (net-like skin discoloration), ankle edema, and hallucinations

Commonly Confused Points

Medication Comparisons

Dopamine Agonists vs. Levodopa

Feature Dopamine Agonists Levodopa
Efficacy Moderate High (gold standard)
Motor complications Less common More common with long-term use
Psychiatric side effects More common (impulse control disorders) Less common
Initial therapy for Younger patients (<65 years) Older patients, more severe symptoms
Dosing frequency 1-3 times daily 3-6 times daily (in advanced disease)

COMT Inhibitors vs. MAO-B Inhibitors

Feature COMT Inhibitors MAO-B Inhibitors
Mechanism Extend levodopa half-life peripherally Prevent dopamine breakdown centrally
Use as monotherapy Never used alone Can be used alone in early disease
Major drug interactions Few significant interactions Meperidine, SSRIs, SNRIs (serotonin syndrome)
Monitoring requirements Liver function (tolcapone) Blood pressure
Distinctive side effect Orange urine discoloration Insomnia (selegiline)

Key Points

  • COMT inhibitors are ALWAYS given with levodopa, while MAO-B inhibitors can be used alone
  • Dopamine agonists have higher risk of impulse control disorders than levodopa
  • Anticholinergics primarily help tremor, while dopaminergic drugs help all motor symptoms

Nursing Considerations

Administration & Monitoring

  • Timing of medication administration is critical for Parkinson's disease patients, as delays can result in significant "off" periods with increased motor symptoms and reduced mobility.
  • Protein intake may interfere with levodopa absorption, so some patients benefit from taking levodopa 30-60 minutes before meals or with low-protein snacks.

    Patient Assessment Steps

  1. Assess baseline vital signs, especially orthostatic blood pressure changes
  2. Document current motor symptoms (tremor, rigidity, bradykinesia, gait) using a standardized scale
  3. Evaluate for non-motor symptoms (cognitive status, mood, sleep, autonomic function)
  4. Review medication timing in relation to meals and symptom patterns
  5. Assess for adverse effects of current medications

Key Points

  • Never abruptly discontinue antiparkinson medications (can precipitate neuroleptic malignant-like syndrome)
  • Monitor for orthostatic hypotension, especially with levodopa and dopamine agonists
  • Assess for signs of impulse control disorders with dopamine agonists

Important Alert: PD medications should NOT be held when patients are NPO for procedures unless absolutely necessary. Consult with physician for alternative administration routes if needed to prevent severe "off" episodes.

Patient Education

  • Educate patients about the importance of medication adherence and consistent timing to maintain stable dopamine levels and reduce motor fluctuations.
  • Instruct patients and caregivers to maintain a medication diary documenting "on" and "off" periods, which helps healthcare providers optimize medication regimens.

Key Points

  • Warn patients about potential side effects and when to report them
  • Educate about potential drug interactions, especially with over-the-counter medications
  • Advise on non-pharmacological interventions (physical therapy, exercise, speech therapy)

Study Tips

NCLEX Approach

  • For NCLEX questions on Parkinson's medications, focus on understanding the mechanism of action, major side effects, and nursing implications rather than memorizing specific dosages.
  • When answering priority questions, remember that safety concerns (fall risk, orthostatic hypotension) typically take precedence over comfort measures.

Memory Aid: "DANCE for PD Meds"

D - Dopaminergics (levodopa, dopamine agonists)
A - Amantadine (for dyskinesias)
N - Neuronal MAO-B inhibitors (selegiline, rasagiline)
C - COMT inhibitors (extend levodopa action)
E - Eliminate Acetylcholine excess (anticholinergics)

Memory Aid: Dopaminergic Side Effect Pattern

"START LOW, GO SLOW"
S - Somnolence (excessive daytime sleepiness)
L - Lightheadedness (orthostatic hypotension)
G - GI upset (nausea, vomiting)
S - Sleep disturbances (vivid dreams, insomnia)

Key Points

  • Focus on understanding mechanisms rather than memorizing drug names
  • Learn to identify medication classes by their suffixes (e.g., -giline for MAO-B inhibitors)
  • Connect medications to their primary target symptoms (e.g., anticholinergics primarily for tremor)

Common Pitfalls

Common Pitfall #1: Confusing the contraindications of anticholinergics (glaucoma, BPH, dementia) with those of dopaminergic medications.

Common Pitfall #2: Failing to recognize that protein can interfere with levodopa absorption but not with dopamine agonists.

Common Pitfall #3: Missing the connection between dopamine agonists and impulse control disorders, which are less common with other PD medications.

Quick Check

  1. Which medication for PD must always be given with levodopa?
    AnswerCOMT inhibitors (entacapone, tolcapone)
  2. Which class of PD medications is most likely to cause impulse control disorders?
    AnswerDopamine agonists (pramipexole, ropinirole)
  3. What is the most serious potential complication of abruptly stopping PD medications?
    AnswerNeuroleptic malignant-like syndrome

Self-Assessment

Knowledge Checklist

  • I can explain the pathophysiology of Parkinson's disease
  • I understand the mechanism of action for each class of PD medications
  • I can identify major side effects of each medication class
  • I know the key nursing considerations for patients on PD medications
  • I can explain the differences between dopamine agonists and levodopa
  • I understand how COMT inhibitors and MAO-B inhibitors differ
  • I know which medications help with levodopa-induced dyskinesias
  • I can identify important drug interactions with PD medications
  • I understand the significance of medication timing in PD
  • I can provide appropriate patient education for PD medications

Remember, understanding Parkinson's disease medications is crucial for providing quality care to these patients. The medication regimen is often complex and individualized, but mastering these concepts will help you make a significant difference in your patients' quality of life. You've got this!

다음 이론을 계속 학습하려면 로그인하세요.

로그인하고 계속 학습
컨텐츠를 그만볼래?

필기노트, 하이라이터, 메모는 잘 쓰고 있어?

내보내줘
어떤 폴더에 저장할래?

컨텐츠 노트에는 총 0개의 폴더가 있어!

폴더 만들기
컨텐츠 만들기
만들기
신고했어요.

운영진이 검토할게요!

해당 유저를 차단했어요.

마이페이지에서 차단한 회원을 관리할 수 있어요.